Literature DB >> 35103906

Role of Omicron variant of SARS-CoV-2 in children in Germany.

Stefan Bittmann1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35103906      PMCID: PMC8804670          DOI: 10.1007/s12519-021-00511-3

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   9.186


× No keyword cloud information.
A new variant of SARS-CoV-2, B.1.1.529 was first reported by the South African Department of Health on Nov 24, 2021. This new variant was named as B.1.1.529 Omicron and was classified as a variant of concern (VOC) by the World Health Organization (WHO) on Nov 26, 2021 [1-13]. Phylogenetic studies showed that Omicron arose independently of the currently dominant delta variant. It has an unusually high number of approximately 30 changes of amino acids in the spike protein compared with the original SARS-CoV-2, including those with known phenotypic impact (increase in transmission, immune evasion, and transmissibility), but significances of many mutations are still unclear[4-7]. The variant has already been detected in several countries worldwide, including Germany [2, 3]. Up to Dec 8, 2021, only 15 cases of Omicron infections were determined from the Robert Koch Institute in Berlin (EU/EEA total 337 cases).  On Dec 23, 2021, 3198 Omicron infections were found [1], which represents an increase of 34% in number of cases (+810 cases) than the previous day. Concerning the age of children infected with Omicron variant, 66 were aged 0–4 years, 288 aged 5–14 years and 1501 aged 15–34 years (till Dec 23, 2021) [1]. Reinfections with Omicron were found in two patients (5–14 years old age group) [1]. No children infected with the Omicron variant were fatal till Dec 23, 2021 [1]. So far, the Omicron variant is not known to be more contagious. The number of infected persons and thus also of children will increase dramatically. However, it is not yet clear whether Omicron also leads more frequently to severe courses of disease [1-13]. If Omicron makes people less ill, it is possible that more children will be hospitalized than is the case now simply because of the high number of infected cases. The statement by Health Minister Karl Lauterbach of Germany that "the Omicron variant is particularly dangerous for children and would lead to high hospitalization rates" is obviously not supported by facts. Lauterbach is apparently referring to a study from South Africa and its reception in Indian media. According to the virologist Klaus Stöhr, with whom the Berliner Zeitung spoke on the subject, the study was pre-published on Dec. 5 and then excerpts were also presented at a meeting of the World Health Organization (WHO) on Dec. 7. WHO announced that Omicron is spreading, but the number of severe cases in South Africa remains low. The very limited data from the study would suggest that the course of the disease may well be milder. This is concluded because very many patients, including many children and adolescents, tested positive for corona only at the hospital on admission but were actually admitted for other reasons. The New York Times reported that the proportion of asymptomatic and mild disease was, therefore, apparently much higher than that in previous waves, according to the initial observations. The portrayal that children were being affected by Omicron misses the data. The Indian media are also very cautious about drawing conclusions. The current data worldwide do not yet say anything reliable about the dangerousness of the variant or the degree of hospitalization. The medical treatment seems not extraordinary different from Covid-19. Oxygen, interleukin-6 inhibitors, JAK inhibitors and other therapies should also play an important role as treatment options. Omicron is a new viral variant with an unpredictable outcome. Time will show further severity in the pediatric population.
  11 in total

1.  Covid-19: Omicron and the need for boosters.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2021-12-14

2.  How severe are Omicron infections?

Authors:  Heidi Ledford
Journal:  Nature       Date:  2021-12       Impact factor: 49.962

3.  Omicron: A Speculation on Its Potential Superpowers.

Authors:  Rodney S Russell
Journal:  Viral Immunol       Date:  2021-12       Impact factor: 2.257

Review 4.  OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear.

Authors:  Vikram Thakur; Radha Kanta Ratho
Journal:  J Med Virol       Date:  2021-12-30       Impact factor: 2.327

5.  Audio Interview: The Omicron Variant of SARS-CoV-2.

Authors:  Eric J Rubin; Lindsey R Baden; Salim S Abdool Karim; Stephen Morrissey
Journal:  N Engl J Med       Date:  2021-12-02       Impact factor: 91.245

6.  Omicron sparks a vaccine strategy debate.

Authors:  Jon Cohen
Journal:  Science       Date:  2021-12-23       Impact factor: 47.728

7.  Omicron SARS-CoV-2 variant: What we know and what we don't.

Authors:  Valentine Marie Ferré; Nathan Peiffer-Smadja; Benoit Visseaux; Diane Descamps; Jade Ghosn; Charlotte Charpentier
Journal:  Anaesth Crit Care Pain Med       Date:  2021-12-10       Impact factor: 4.132

8.  The effects of the silence on south African children and adolescents against a global alert on the newly identified coronavirus variant: Omicron.

Authors:  Danielly Gonçalves Sombra Lima; Thânia Maria Rodrigues Figueiredo; Yara Talita Gomes Pereira; Maria Auxiliadora Ferreira Brito Almino; Liliany Medeiros Pereira; Hildson Leandro de Menezes; Jaime Emanuel Brito Araújo; Jucier Gonçalves Junior; Nélio Barreto Vieira; Sionara Melo Figueiredo de Carvalho; Sávio Samuel Feitosa Machado; Cícera Janielly de Matos Cassiano; Barbara Silveira Dionizio; Raul Cesar Fortaleza Pinheiro; Pedro Walisson Gomes Feitosa; Francisco Helder Pereira Filho; Nádia Nara Rolim Lima; Modesto Leite Rolim Neto
Journal:  J Pediatr Nurs       Date:  2021-12-17       Impact factor: 2.523

9.  Omicron: a drug developer's perspective.

Authors:  Fang Flora Fang; Pei-Yong Shi
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

View more
  4 in total

1.  [Strengthening the prevention and treatment of Omicron infection in children].

Authors:  Fu-Yong Jiao; Lei Ma
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

2.  Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C.

Authors:  Juanjie Tang; Tanya Novak; Julian Hecker; Gabrielle Grubbs; Fatema Tuz Zahra; Lorenza Bellusci; Sara Pourhashemi; Janet Chou; Kristin Moffitt; Natasha B Halasa; Stephanie P Schwartz; Tracie C Walker; Keiko M Tarquinio; Matt S Zinter; Mary A Staat; Shira J Gertz; Natalie Z Cvijanovich; Jennifer E Schuster; Laura L Loftis; Bria M Coates; Elizabeth H Mack; Katherine Irby; Julie C Fitzgerald; Courtney M Rowan; Michele Kong; Heidi R Flori; Aline B Maddux; Steven L Shein; Hillary Crandall; Janet R Hume; Charlotte V Hobbs; Adriana H Tremoulet; Chisato Shimizu; Jane C Burns; Sabrina R Chen; Hye Kyung Moon; Christoph Lange; Adrienne G Randolph; Surender Khurana
Journal:  Nat Commun       Date:  2022-05-27       Impact factor: 17.694

3.  Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C.

Authors:  Juanjie Tang; Adrienne G Randolph; Tanya Novak; Tracie C Walker; Laura L Loftis; Matt S Zinter; Katherine Irby; Surender Khurana
Journal:  Vaccines (Basel)       Date:  2022-02-10

Review 4.  Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention.

Authors:  Ailan Xu; Bixia Hong; Fuxing Lou; Shuqi Wang; Wenye Li; Amna Shafqat; Xiaoping An; Yunwei Zhao; Lihua Song; Yigang Tong; Huahao Fan
Journal:  MedComm (2020)       Date:  2022-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.